US$ 21.70
parkinson glutathione oxidative ipsc crispr CRISPR/Cas9 assisted stem cell therapy in Parkinson's disease CRISPR-Cas9-Based Technology and Its Relevance
Description
Villalta et al., 2009)

Gutmann DH, Collins FS

M.Vaquero-LorenzoC.Baca-GarciaE

S.GabbrielliR

Morbilliform rash, eschar, splenomegaly, and lymphadenopathies are typical signs

Similar to what is observed in monocytes and macrophages, G6PD-d may limit the production of NADPH-dependent ROS that act as second messengers to enhance NFAT, AP-1, and NFB signaling 89,116,117
